Pembrolizumab for Rare and Ultra-Rare Sarcomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial
Lancet Oncol 2023 Jul 07;[EPub Ahead of Print], JY Blay, S Chevret, A Le Cesne, M Brahmi, N Penel, S Cousin, F Bertucci, E Bompas, T Ryckewaert, P Soibinet, P Boudou-Rouquette, E Saada Bouzid, P Soulie, T Valentin, JP Lotz, D Tosi, Z Neviere, M Cancel, I Ray-Coquard, L Gambotti, F Legrand, A Lamrani-Ghaouti, C Simon, C Even, C MassardFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.